Clinical trial
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory…
NCT00151073 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00151073 |
|---|---|
| Title | Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate |
| Official title | An Evaluation of Estramustine, Docetaxel and Zoledronate in Patients With Hormone-Refractory Adenocarcinoma of the Prostate |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Aventis Pharmaceuticals Industry Novartis |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hormone-Refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid, Estramustine, Docetaxel |
| Enrollment | 28 |
| Start date | Apr 1, 2002 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 22, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: